Register Now

Joseph Shultz

Vice President of Technical Development and Manufacturing
Ottimo Pharma

View Bio

Panelist

Joseph Shultz

Joseph Shultz is the vice president of technical development and manufacturing at Ottimo Pharma. His more than 30 years in the industry span development, manufacturing, quality, and technology development. He has held influential positions at Amgen, Novartis Pharma, the Battelle Memorial Institute, Evelo Biosciences, and Resilience. He initiated the technologies and led the strategies that resulted in next-generation biomanufacturing plants at both Amgen and Novartis.

Close

Imroz Ghangas

Vice President of Commercial Sales
Asimov

View Bio

Panelist

Imroz Ghangas

Imroz Ghangas and his team drive partnerships to advance Asimov’s genetic design platform and AI capabilities. With over 25 years in biotech, Imroz has evolved from process development scientist to commercial leader, bridging technical innovation with scalable solutions. His expertise spans bioprocess development and platform integration, with deep knowledge of biomanufacturing workflows from gene to drug product. He leverages his technical foundation to accelerate the adoption of next-generation bioprocessing technologies.

Close

• Time: 10:00 PDT, 13:00 EDT, 17:00 GMT

Complex biologics such as bifunctional antibodies are opening new therapeutic possibilities in oncology, but these molecules present significant challenges for manufacturing teams. Non-standard architectures can often translate to low expression and difficult developability, making cell line development a critical bottleneck between a promising sequence and a viable clinical candidate.

In this GEN webinar, Joseph Shultz (vice president of technical development and manufacturing, Ottimo Pharma) and Imroz Ghangas (vice president of commercial sales, Asimov) discuss strategies for achieving high-performing clonal titers and advancing a dual-paratopic cancer immunotherapy from sequence to dosed patient in under a year. Attendees will learn about the unique attributes of Ottimo’s molecule and how a specialist partnership with Asimov accelerated the program. The presenters will also introduce the CHO Edge System, which combines Asimov’s proprietary GS knock-out CHO host, hyperactive transposase, library of characterized genetic elements, and AI-driven genetic design tools to routinely deliver clonal titers of 8-12 g/L.

A live Q&A session will follow the presentation offering you a chance to pose questions to our expert panelists.

Produced with support from:

The post From Sequence to Patient in Under 12 Months: A Case Study in Advancing Complex Cancer Immunotherapies appeared first on GEN – Genetic Engineering and Biotechnology News.

Vyriad reports that it will showcase its latest CAR T delivery technology platform, G-Link, through a schedule of presentations, technical sessions, and exhibition activities at ASGCT. The modular plug-and-play protein adapter developed in collaboration with Menachem Rubenstein, PhD, of the Weizmann Institute allows drug developers to cap and retarget existing lentiviral vectors for in vivo delivery, according to the company.

By leveraging G-Link, wild-type lentiviral vectors can be reprogrammed for in vivo applications without the need for intensive vector re-engineering, effectively shortening development timelines for next-generation CAR T and other cell therapies, notes a company spokesperson, who adds that G-Link can also be used to simplify ex vivo CAR T manufacturing and significantly improve T cell transduction efficiency without redesigning vectors.

“I believe that G-Link can address some of the most persistent challenges in in vivo delivery and we are excited to unveil it at ASGCT this year,” says Stephen Russell, PhD, CEO of Vyriad. “Our participation this year underscores our clear mission: to replace complex, weeks-long manufacturing cycles with precise, off-the-shelf immunotherapies. With G-Link, we aim to foster collaborations that will define the next generation of in vivo cell therapies.”

Vyriad’s VV169 in vivo CAR T program will progress into clinical development later this year, while the G-Link platform will advance towards clinical translation later in the future, continues Russell.

The post G-Link CAR-T Delivery Platform Showcased at ASGCT appeared first on GEN – Genetic Engineering and Biotechnology News.

Even though Elevidys beat Wall Street expectations, analysts expect investor focus to shift toward Sarepta’s early-stage RNA drugs.